M
maceration increase in bulk (with softening) of the stratum corneum; caused by prolonged exposure to sweat or induced by topical application of hydrolysing or caustic chemicals, in treatment of verrucae or corn
macrocirculation circulation of blood through larger vessels (arteries and veins) – see microcirculation
macrocyte; megaloblast abnormal, large erythrocyte characteristic of pernicious anaemia
macroglossia tongue enlargement, as in hypothyroidism
macromelia abnormal enlargement of one limb; rare cause of leg length discrepancy
macromolecule large molecule, e.g. a protein, globulin, nucleic acid or polysaccharide
macroscopic visible to the naked eye
macrovascular disease see atherosclerosis
macula small, sessile, discoloured skin patch
macula lutea oval area of retina adjacent to optic disc
maculopapule broad-based, sessile skin lesion with central raised papule
maculopathy any pathological condition of macula lutea; e.g. diabetic retinal disease
maggot therapy see larval therapy
magnesium sulphate see Epsom salts
Magnetopulse device generating a pulsed magnetic field within targeted tissues; used to gain symptomatic relief of injury and inflammation, or to increase blood flow to specific tissue areas (Table M1); contraindicated in diabetes, pacemakers, pregnancy or history of thrombosis
‘major tranquillizers’ see neuroleptics
-malacia softening/loss of tissue consistency/contiguity, e.g. osteomalacia; chondromalacia
Malassezia furfur causative fungal organism of pityriasis versicolor (tinea versicolor), see pityriasis versicolor
malathion topical treatment for ectoparasite infection (e.g. scabies, head and body lice [crabs])
malformation failure of normal development
malignant locally invasive, destructive, neoplastic growth; can undergo metastasis
malignant melanoma see melanoma
malunion incomplete/misaligned post-injury bone union
management plan; MP proposed and written course of short-term and long-term treatment regimes linking the patient examination and diagnosis to resolution of patient’s presenting condition; should be agreed by both practitioner and patient, and include an outline of all treatments likely to be included, estimates of treatment success rates, likelihood of recurrence of condition and/or need for further or ongoing treatments, and the frequency of those treatments; it should also note any items of (written) information or verbal advice given to the patient, specify any discipline to whom patient should be referred, and also detail any treatment area to be undertaken by the patient him- or herself; therapies indicated in the MP plan should be supported by evidence-based medicine, local protocols, treatment algorithms and similar; MP is retained in patient notes, copied to referring practitioner, reviewed regularly (e.g. after specified number of visits) and a list of the range of other possible options recorded if initial interventions are unsuccessful or problem recurs (e.g. referral to another specific discipline for a named form of therapy/advice) (Table M2)
Feature | Detail/explanation |
---|---|
Main presenting complaint | 9-year-old girl presents with 3-week history consisting of pain in the medial (tibial) sulcus of the left hallux since ‘picking’ nail Otherwise fit (i.e. no other significant medical history; no regular medications) Advised to contact you by GP |
Examination | Local tenderness, inflammation and swelling at medial area of left hallux; no signs of obvious infection; medial side of nail plate very ragged as a result of onychotillomania Vascular examination: normal Neurological examination: normal Dermatological examination: mild hyperhidrosis in both feet Biomechanical assessment: fully compensated rearfoot varus; no joint pathologies Social assessment: dance and gymnastics twice a week Footwear assessment: trainers (one size too small); laces not tied |
Diagnostic tests | None indicated |
Management plan | Short-term plan Explanation of likely cause of current problem (picking nails, hyperhidrotic skin, short, unlaced shoes, excess pronation) 1. Immediate treatment: exploration of both sides of both first toenails, and reduction of ragged edges with Black’s file + LA is necessary, with patient/parental consent. Advise regime of daily warm saline foot baths and demonstration to mother on how to pack affected sulcus with cotton wool. Review in 7 days (or SOS) 2. Advice Exercise advice: no gym/sport/dance before next appointment Shoe advice (give leaflet) – needs a larger trainer, and needs to tie laces so that rearfoot is retained in the heel cup of the shoe Skin care advice (treatment/avoidance of hyperhidrosis) – give leaflet 3. Temporary insole with medial felt (cobra) pad to minimize hallux trauma due to excess compensatory pronation/foot lengthening on weight-bearing 4. Letter to GP informing of action to date (copy to notes) Long-term plan Explanation of details of other treatments that may be necessary after next visit 1. Further clearance of medial side of first nail or removal of spike of nail under LA or removal of medial section of first nail under LA and phenolization of exposed pocket of nail matrix + dressings (94% cure rate) + details of aftercare regimes for this range of options 2. Biomechanical and gait evaluation, with provision of bespoke antipronatory orthoses 3. Review patient every 4 months to monitor biomechanical, skin and nail function |
LA, local anaesthetic.
march fracture see fracture, march
Marfan’s syndrome see syndrome, Marfan’s
Marjolin’s ulcer see ulcer, Marjolin’s
marrow soft, fatty, haemopoietic tissue within medullary cavity of long bones
mask (2) several layers of adhesive strapping (with a central hole, matching lesion size); protects surrounding skin from effects of ointment-based caustic agents applied to e.g. verrucae; Figure M1
mass amount of matter contained by an object
matrix tissue formative element
mattress sutures interrupted sutures that cause minimal tension at wound edges; see Figure H4; Table S6
maturity-onset diabetes mellitus outdated term for type 2 diabetes mellitus
maturity-onset diabetes of the young; MODY presentation of type 2 diabetes mellitus affecting overweight young adults or teenagers, similar to type 2 diabetes of older subjects, but usually without secondary complications (see also diabetes mellitus and type 2 diabetes mellitus)
maximum safe dose; MSD body mass-related maximum dose (of a pharmacological agent) that can be administered within a 24-hour period, usually quoted for a 70-kg adult; calculated as the product of body mass and the amount or percentage mass of drug used (Tables M3–M5); MSD cannot be increased in a patient weighing >70 kg, and must be reduced proportionally for patients weighing <70 kg, or with reduced liver/kidney function, or concurrently using e.g. beta-blockers, antiarrhythmic drugs or central nervous system-acting drugs (Table M3)
Agent (brand name) | Maximum safe dose (70-kg adult) | Dose per kg of body mass |
---|---|---|
Lidocaine (Xylocaine) | 200 mg | 3 mg/kg |
Bupivacaine (Marcain) | 150 mg | 2 mg/kg |
Levo-bupivacaine (Chirocaine) | 150 mg | 2 mg/kg |
Mepivacaine (Scandonest) | 400 mg | 6 mg/kg |
Prilocaine (Citanest) | 400 mg | 6 mg/kg |
Ropivacaine (Naropin) | 250 mg | 3.5 mg/kg |
Mayo block; first-ray block see anaesthesia, first-ray block
mean cell volume; MCV mean erythrocyte volume; calculated from the haematocrit and red cell count
mechanoreceptors specialized sensory nerve endings at termini of A-beta nerve fibres; preferentially subserve mechanosensation, e.g. touch, vibration (see Table S2)
medial ankle ligament see deltoid ligament; Table A7
medial arterial calcification; MAC see Mönckeberg’s sclerosis
medial dorsal cutaneous nerve terminal branch of superficial peroneal nerve; innervates medial aspect of first ray and second intermetatarsal space; may become compressed (entrapped) at first metatarsal–medial cuneiform joint area, causing dermatomal distal paraesthesia and pain (see intermediate dorsal cutaneous nerve)
medial dorsal cutaneous nerve block see anaesthesia, superficial peroneal
medial forefoot wedge wedge of material (clinical padding or orthosis) that fills the potential space between medial plantar forefoot and underlying support surface, and resists compensatory forefoot pronation; terminal part of medial sole wedge (see cobra pad)
medial knee pain pain and discomfort at medial knee joint area, secondary to strain imposed by excess foot pronation (see Table K3)
medial longitudinal arch; MLA D-shaped concavity (in frontal and sagittal planes), at middle one-third of medial plantar aspect of foot; extends from distal limit of heel to just proximal to head of first metatarsal, and from medial (inner) border of foot to just medial to plantar cuboid (see Figure C3, Table A7)
medial longitudinal arch height sagittal-plane height of medial longitudinal arch is determined by calcaneal angle of inclination, talar pitch and first metatarsal angle of declination; the navicular functions as the arch ‘keystone’ (see Figure C3)
medial plantar nerve medial division of terminal branches of tibial nerve; subserves medial plantar area, except medial area of medial longitudinal arch and plantar surface of heel (see Figure D1)
medial sole wedges see cobra pad
medial support strapping soft splint formed from 2.5-cm-wide elastic strapping, applied as a ‘stirrup’ to hind- and midfoot (with foot held in inversion; ± valgus filler pad) as short-term management of chronic medial ankle pain/trauma, or chronic plantar fasciitis (Figure M2)
medial tibial stress syndrome; MTSS see syndrome, medial tibial stress (Tables M6 and M7)
Grade | Characteristic |
---|---|
1 | Pain on palpation of the anteromedial (or posteromedial) area of tibial crest No pain during activity or exercise |
2 | Pain after activity or exercise No pain during activity or exercise |
3 | Pain during activity or exercise Pain after activity or exercise |
4 | Pain and discomfort during normal walking Continual pain during activity or exercise |
Presentation | Treatment |
---|---|
Phase 1: acute phase | Cessation of exercise activity until all pain resolves RICE(P) |
Phase 2: rehabilitation phase | Deep compartment muscle exercise to strengthen the deep fascial–bone interface and reduce tension on the deep fascial insertion, in order to decrease pain and swelling and prevent fascial scarring |
Phase 3: functional phase | Use of antipronatory/functional orthoses, strapping or taping in order to strengthen the fascial–bone interphase and prevent further excessive tension on the tibia |
Phase 4: return to activity | Phased and gradual return to normal levels of activity |
median plane see cardinal planes of the body
Medical Devices Agency; MDA UK competent authority for manufacture of medical devices (e.g. bespoke orthoses); EEC Directive 93/42 requires that all manufacturers are registered with the MDA, and that all manufactured orthoses carry the CE mark (see Box C1)
medical emergencies unexpected clinical emergencies arising as a result of, or during, treatment (Table M8)
Clinical event | Example actions to minimize the incidence of clinical emergency event |
---|---|
Pretreatment patient screening | Knowledge of patient’s current medical history • Cardiovascular pathology • Respiratory disease • Renal problems • Endocrine disease • Current medications regime • Social history (cigarette smoking; alcohol) |
Resuscitation | In-clinic availability of: • Oxygen • Portable defibrillator • Injectable adrenaline Clinician training • Basic life support • Immediate life support • Advanced life support |
Intraoperative monitoring | Staff team training • Designated roles to be taken in the event of clinical emergency Recognition of incident emergencies and actions protocols • Cardiac arrest • Vasovagal attack/faint • Anaphylaxis • Hypoglycaemia • Local anaesthetic overdose • Hypovolaemia |
Medical Exposures Directive Council Directive 97/43/Euratom of 30 June 1997; revoked 1988 Ionizing Radiation Regulations
medical history information given by patient (and/or patient’s partner/carer/parent/referring practitioner), detailing the patient’s current and past health status (Table M9)
History element | Additional information |
---|---|
Introductory information | Demographics (age, sex, race, place of birth, marital status, occupation, religion, next of kin) |
Main presenting complaint | The problem that has prompted the patient to request the consultation (and/or additional information supplied by referrer) |
Past history | |
Medical | General state of health, childhood illnesses, adult illnesses, psychiatric illnesses, accidents and injuries, operations and hospitalizations (list surgical procedures in chronological order) |
Podiatric | Previous foot/limb problems and treatments received |
Current health status | Current GP or hospital clinics attended Current allied health professional clinics attended Alternative therapists attended |
Drugs/medications history | Current and previous prescription-only medicine regimes Current and recent over-the-counter regimes Allergies and hypersensitivity history |
Family history | Health and age of siblings/parents/children Ages and causes of death of parents/grandparents |
Social history | Smoking/alcohol/recreational drug consumption Hobbies and recreational activities |
General systems review: CRANGLES | C = cardiovascular system (e.g. history of heart problems, high blood pressure, previous rheumatic fever, heart murmurs, arrhythmias/palpitation, chest pain/angina, blood dyscrasias, peripheral arterial disease [intermittent claudication, leg cramps, rest pain], venous incompetence, lymphatic dysfunction) R = respiratory system (e.g. history of asthma, bronchitis, emphysema, tuberculosis) A = alimentary system (e.g. history of weight change, indigestion, gastric/duodenal ulcer, liver or gallbladder problems, irritable bowel, constipation) N = central and peripheral nervous system (e.g. history of stroke, nerve injury, any psychiatric problems, fatigue and sleep alteration) G = genitourinary system (e.g. polyuria, nocturia, pain on urination) L = locomotor (musculoskeletal) system (e.g. joint or muscle pain, morning stiffness, arthritis, gout, lower-back pain) E = endocrine system S = skin (rashes, lumps, sores, itching, dryness, colour changes, changes in hair/nails/sweat pattern) |
Foot and lower-limb systems review | Vascular review (arteries, veins, lymphatics) Neurological review (sensory, motor, autonomic) Biomechanical review Dermatological review Overall impression of status of tissues of the foot and lower limb |
medicolegal legal requirements inherent within practice of podiatry
mediolateral oblique projection see Table R1
meiosis reduction division; see chromosomes
Meissner corpuscles specialized endings at A-beta sensory nerves; lie within upper poles of dermal papillae; subserve light touch skin sensation Table S2
Melaleuca alternifolia tea tree bush
melanin dark brown/black pigment within melanosomes of epidermal melanocytes (see melanosome)
melanocytes neural tube-derived, melanin-producing cells of dermoepidermal junction and stratum germinativum; characterized by long branching dendritic processes (see melanosome)
melanoma malignant neoplasm of melanocytes; capable of widespread metastasis (see Table C13)